Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992995 | 0.87 | EPHX2 (0.56) | EPHX2CYP2C9 | |
| SCHEMBL30924094 | 0.86 | EPHX2 (0.79) | EPHX2 | |
| SCHEMBL3652853 | 0.85 | EPHX2 (0.57) | EPHX2CYP2C9 | |
| SCHEMBL30924118 | 0.85 | EPHX2 (0.77) | EPHX2 | |
| SCHEMBL1815988 | 0.85 | POLB (0.64) | EPHX2 | |
| SCHEMBL20942627 | 0.85 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL3189606 | 0.84 | EPHX2 (0.58) | EPHX2 | |
| SCHEMBL30924128 | 0.84 | EPHX2 (0.75) | EPHX2CYP2C9 | |
| SCHEMBL3474671 | 0.82 | EPHX2 (0.60) | EPHX2CYP2C9 | |
| SCHEMBL1815968 | 0.82 | KDM4E (0.54) | EPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311776-A1 | Novel sEH Inhibitors and their Use | SMITHKLINE BEECHAM CORPORATION | 2010-12-09 | — | — | US | disclosed |
| EP-2240025-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009097475-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311776-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, FAH | EPHX2 5/4885CYP2C9 185/4885 |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | EPHX1, NCEH1, FAH | EPHX2 4/4885CYP2C9 160/4885 |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | EPHX2 4/4885CYP2C9 160/4885 |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | EPHX2 5/4885CYP2C9 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.